From: Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy
Name | Target | Signaling pathway | Effect |
---|---|---|---|
PD-1/PD-L1 Anitibodies | PD-1/PD-L1 | PI3K/Akt/mTOR | Teffs: increase FAO |
Tumor: inhibit glycolysis | |||
CTLA-4 Antibodies | CTLA-4 | PI3K/Akt/mTOR | Teffs: inhibit glucose uptake |
Imatinib | BCR-ABL kinase/IDO | BCR/ABL IDO | Teffs: activate |
Treg: apoptosis | |||
Tumor: switching from glycolysis to OXPHOS | |||
Metformin | PD-L1 | LKB1-AMPK system mTOR | Tumor: down-regulate PD-L1 expression |
PIM kinase inhibitor | PIM kinase | mTORC1 | Teffs: increase glucose uptake |
Enzyme phosphoenolpyruvate carboxykinase-1 | Phosphoenolpyruvate | Sarco/ER Ca(2+)-ATPase (SERCA) activity | Teffs: upregulate the effector function |
MVK inhibitor | MVK | PI3K/Akt/mTOR | Teffs: promote activation |
Tumor: inhibit | |||
Avasimibe | ACAT-1 | Cholesterol esterification | Teffs: activate |
Tumor: inhibit the proliferation and metastasis | |||
GDC-0919 | IDO1 | tryptophan | Teffs: relieves CD8+ T cell inhibition |
INCB024360 | IDO | tryptophan | Teffs: increase proliferation and IFN-γ production |
N-acetylcysteine | FOXO1 | PI3K/Akt/mTOR | Teffs: affect granzyme B secretion and PD-1 expression |